The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Metformin and Its Benefits for Various Diseases
Open accessAbstract
Metformin is a widely used biguanide drug due to its safety and low cost. It has been used for over 60 years to treat type 2 diabetes at the early stages because of its outstanding ability to decrease plasma glucose levels. Over time, different uses of metformin were discovered, and the benefits of metformin for various diseases and even aging were verified. These diseases include cancers (e.g., breast cancer, endometrial cancer, bone cancer, colorectal cancer, and melanoma), obesity, liver diseases, cardiovascular disease, and renal diseases. Metformin exerts different effects through different signaling pathways. However, the underlying mechanisms of these different benefits remain to be elucidated. The aim of this review is to provide a brief summary of the benefits of metformin and to discuss the possible underlying mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Metformin inhibits mitochondrial complex I (13, 14), which leads to AMPK (adenosine 5- monophosphate—activated protein kinase) activation (15).”
BackgroundAMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Gut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · cited 1×
“Triple negative breast cancer (TNBC) is a kind of breast cancer that is difficult to cure, due to the lack of approved targeted therapies and effective chemotherapy with low toxicity (69).”
BackgroundExtending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Rubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
AMPK: Sensing Glucose as well as Cellular Energy Status
Lin, S.-C., & Hardie, D. G. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.009 · Cited by 1,191
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“Metformin exerts its anti-hyperglycemic effects mostly by suppressing hepatic glucose production through AMPKdependent (36, 37) or -independent pathways (38, 39).”
BackgroundLavine, J. E. (2011) · JAMA · doi:10.1001/jama.2011.520 · Cited by 1,101
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Acute kidney injury and chronic kidney disease: an integrated clinical syndrome
Chawla, L. S., & Kimmel, P. L. (2012) · Kidney International · doi:10.1038/ki.2012.208 · Cited by 829
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Breast Cancer: Epidemiology and Etiology
Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z., & Zhao, J. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0459-6 · Cited by 699
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Moiseeva, O., Deschênes‐Simard, X., St‐Germain, E., Igelmann, S., Huot, G., Cadar, A. E., Bourdeau, V., Pollak, M. N., & Ferbeyre, G. (2013) · Aging Cell · doi:10.1111/acel.12075 · Cited by 654
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630 · cited 1×
“Moreover, a study indicated that in rats, metformin modulates gut microbiota and prevents high-fat diet induced obesity, which increased the abundance of short-chain fatty acid producing bacteria and decreased microbial diversity (90).”
BackgroundRaffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., & Longo, V. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708100105 · Cited by 587
Eggermont, A. M., Spatz, A., & Robert, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60802-8 · Cited by 548
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 484
He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., & Wondisford, F. E. (2009) · Cell · doi:10.1016/j.cell.2009.03.016 · Cited by 481
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Howell, J. J., Hellberg, K., Turner, M., Talbott, G., Kolar, M. J., Ross, D. S., Hoxhaj, G., Saghatelian, A., Shaw, R. J., & Manning, B. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.009 · Cited by 408 · cited 1×
“Moreover, activation of AMPK leads to the inhibition of mTORC1 (mammalian target of rapamycin complex I), which also results in the suppression of gluconeogenesis (42).”
BackgroundLactic Acidosis in Patients with Diabetes Treated with Metformin
Misbin, R. I., Green, L., Stadel, B. V., Gueriguian, J. L., Gubbi, A., & Fleming, G. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380415 · Cited by 403
Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism
Lee, J., Yesilkanal, A. E., Wynne, J. P., Frankenberger, C., Liu, J., Yan, J., Elbaz, M., Rabe, D. C., Rustandy, F. D., Tiwari, P., et al. (2019) · Nature · doi:10.1038/s41586-019-1005-x · Cited by 380
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372
The blooming of the French lilac
Witters, L. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14178 · Cited by 367
Lamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Heme Induces Ubiquitination and Degradation of the Transcription Factor Bach1
Zenke-Kawasaki, Y., Dohi, Y., Katoh, Y., Ikura, T., Ikura, M., Asahara, T., Tokunaga, F., Iwai, K., & Igarashi, K. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02415-06 · Cited by 336
Song, Y. M., Lee, Y.-H., Kim, J.-W., Ham, D.-S., Kang, E.-S., Cha, B. S., Lee, H. C., & Lee, B.-W. (2015) · Autophagy · doi:10.4161/15548627.2014.984271 · Cited by 332
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.5 · Cited by 320
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 316
Kisfalvi, K., Eibl, G., Sinnett-Smith, J., & Rozengurt, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0418 · Cited by 315
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313
Shi, W.-Y., Xiao, D., Wang, L., Dong, L.-H., Yan, Z.-X., Shen, Z.-X., Chen, S.-J., Chen, Y., & Zhao, W.-L. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.13 · Cited by 308 · cited 1×
“human lymphoma by inhibiting mTOR signaling without the involvement of AKT, and the suppression of mTOR subsequently leads to the suppression of growth of B cells and T cells (75).”
BackgroundRowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299
Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Zhang, Z.-J., Zheng, Z.-J., Kan, H., Song, Y., Cui, W., Zhao, G., & Kip, K. E. (2011) · Diabetes Care · doi:10.2337/dc11-0512 · Cited by 291
Metformin activates AMPK through the lysosomal pathway
Zhang, C.-S., Li, M., Ma, T., Zong, Y., Cui, J., Feng, J.-W., Wu, Y.-Q., Lin, S.-Y., & Lin, S.-C. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.003 · Cited by 280
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Batandier, C., Guigas, B., Detaille, D., El-Mir, M., Fontaine, E., Rigoulet, M., & Leverve, X. M. (2006) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9003-8 · Cited by 279
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC
Blandino, G., Valerio, M., Cioce, M., Mori, F., Casadei, L., Pulito, C., Sacconi, A., Biagioni, F., Cortese, G., Galanti, S., et al. (2012) · Nature Communications · doi:10.1038/ncomms1859 · Cited by 242
Gunton, J. E., Delhanty, P. J. D., Takahashi, S.-I., & Baxter, R. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021394 · Cited by 234
Guo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12265 · Cited by 225
Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Cerezo, M., Tichet, M., Abbe, P., Ohanna, M., Lehraiki, A., Rouaud, F., Allegra, M., Giacchero, D., Bahadoran, P., Bertolotto, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1226-t · Cited by 222
Metformin – its potential anti-cancer and anti-aging effects
Podhorecka, M., Ibanez, B., & Dmoszyńska, A. (2017) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0010.3801 · Cited by 203
The rise and fall of aspirin in the primary prevention of cardiovascular disease
Raber, I., McCarthy, C. P., Vaduganathan, M., Bhatt, D. L., Wood, D. A., Cleland, J. G. F., Blumenthal, R. S., & McEvoy, J. W. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30541-0 · Cited by 177
Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., Borger van der Burg, B., Donker, A. J. M., & Stehouwer, C. D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2133 · Cited by 175
Mohan, M., Al-Talabany, S., McKinnie, A., Mordi, I. R., Singh, J. S. S., Gandy, S. J., Baig, F., Hussain, M. S., Bhalraam, U., Khan, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz203 · Cited by 170
Charpentier, G., Fleury, F., Kabir, M., Vaur, L., & Halimi, S. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00582.x · Cited by 166
Lee, M., Katerelos, M., Gleich, K., Galić, S., Kemp, B. E., Mount, P. F., & Power, D. A. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010050 · Cited by 165
AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts
Lee, Y., Kim, Y.-S., Lee, S.-Y., Kim, G.-H., Kim, B., Lee, S., Lee, K., Kim, G.-S., Kim, S., & Koh, J. (2010) · Bone · doi:10.1016/j.bone.2010.08.001 · Cited by 164
Diabetes drugs and neurological disorders: new views and therapeutic possibilities
Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 160
Metformin is associated with improved survival in endometrial cancer
Ko, E. M., Walter, P., Jackson, A., Clark, L., Franasiak, J., Bolac, C., Havrilesky, L. J., Secord, A. A., Moore, D. T., Gehrig, P. A., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.021 · Cited by 158
Rosenstock, J., Chuck, L. H. S., González-Ortíz, M., Merton, K., Craig, J., Capuano, G. A., & Qiu, R. (2016) · Diabetes Care · doi:10.2337/dc15-1736 · Cited by 144
Metformin and ageing: improving ageing outcomes beyond glycaemic control
Valencia, W. M., Palacio, A., Tamariz, L., & Florez, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4349-5 · Cited by 142
Polak, R., & Buitenhuis, M. (2011) · Blood · doi:10.1182/blood-2011-07-366203 · Cited by 137
Søfteland, E. W., Meier, J. J., Vangen, B., Toorawa, R., Maldonado‐Lutomirsky, M., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-1347 · Cited by 130
Jagannathan, S., Abdel-Malek, M. A. Y., Malek, E., Vad, N. M., Latif, T., Anderson, K. C., & Driscoll, J. J. (2015) · Leukemia · doi:10.1038/leu.2015.157 · Cited by 118
Kim, E., Lee, S., Jhun, J. Y., Byun, J. K., Jeong, J. H., Lee, S.-Y., Kim, J. K., Choi, J. Y., & Cho, M. (2016) · Mediators of Inflammation · doi:10.1155/2016/5813030 · Cited by 108
Metabolic Effects of Metformin in the Failing Heart
Dziubak, A., Wójcicka, G., Wojtak, A., & Bełtowski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102869 · Cited by 104
Kristensen, J. M., Treebak, J. T., Schjerling, P., Goodyear, L. J., & Wojtaszewski, J. F. P. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00417.2013 · Cited by 101
Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment
Sui, X., Xu, Y., Wang, X., Han, W., Pan, H., & Xiao, M. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00577 · Cited by 96
Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice
Karise, I., Bargut, T. C. L., del Sol, M., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.021 · Cited by 96
Lin, Y., Wang, K., Ma, C., Wang, X., Gong, Z., Zhang, R., Zang, D., & Cheng, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00227 · Cited by 92
The multifaceted effects of metformin on tumor microenvironment
Kurelac, I., Ganesh, N. U., Iorio, M. C., Porcelli, A. M., & Gasparre, G. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.010 · Cited by 89
Systematic review: Preventive and therapeutic applications of metformin in liver disease
Bhat, A., Sebastiani, G., & Bhat, M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i12.1652 · Cited by 88
Bell, S., Farran, B., McGurnaghan, S. J., McCrimmon, R. J., Leese, G., Petrie, J. R., McKeigue, P., Sattar, N. A., Wild, S. H., McKnight, J. A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0579-5 · Cited by 85
Neven, E., Vervaet, B. A., Brand, K. M. G., Gottwald‐Hostalek, U., Opdebeeck, B., Maré, A. D., Verhulst, A., Lalau, J., Kamel, S., Broe, M. E. D., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.027 · Cited by 81
Changes of Cell Biochemical States Are Revealed in Protein Homomeric Complex Dynamics
Stynen, B., Abd-Rabbo, D., Kowarzyk, J., Miller‐Fleming, L., Aulakh, S. K., Garneau, P., Ralser, M., & Michnick, S. W. (2018) · Cell · doi:10.1016/j.cell.2018.09.050 · Cited by 66
Gu, S., Shi, J., Tang, Z., Sawhney, M. S., Hu, H., Shi, L., Fonseca, V. A., & Dong, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126704 · Cited by 64
Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro
Breining, P., Jensen, J., Sundelin, E. I. O., Gormsen, L. C., Jakobsen, S., Busk, M., Rolighed, L., Bross, P., Guerra, P. F., Markussen, L. K., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13362 · Cited by 63
Cone, C. J., Bachyrycz, A. M., & Murata, G. H. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p099 · Cited by 61
Li, K., Zhang, T., Wang, F., Cui, B., Zhao, C.-X., Yu, J., Lv, X., Zhang, X., Yang, Z.-N., Huang, B., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0172-9 · Cited by 61
Li, Y., Tan, J., Wang, Q., Duan, C., Hu, Y., & Huang, W. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.09.011 · Cited by 59
AKT as a therapeutic target in multiple myeloma
Keane, N. A., Glavey, S. V., Krawczyk, J., & O'Dwyer, M. E. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.924507 · Cited by 58
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 55
Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics?
Martin, M. J., & Marais, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1677 · Cited by 54
Epidemiology and prevention of cutaneous melanoma
Demierre, M. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0011-z · Cited by 47
Metformin in heart failure patients
Kinsara, A. J., & Ismail, Y. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.05.009 · Cited by 29
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
Papanagnou, P., Stivarou, T., & Tsironi, M. (2016) · Pharmaceuticals · doi:10.3390/ph9020024 · Cited by 26
Kheniser, K. G., Kashyap, S. R., & Kasumov, T. (2018) · Obesity Science & Practice · doi:10.1002/osp4.309 · Cited by 24
G Protein-Coupled Receptor Accessory Proteins and Signaling: Pharmacogenomic Insights
Thompson, M. D., Cole, D. E. C., José, P. A., & Chidiac, P. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_7 · Cited by 21
Cherney, D. Z. I., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.012 · Cited by 18
Lin, Y., Wang, K., Ma, C., Wang, X., Gong, Z., Zhang, R., Zang, D., & Cheng, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00322 · Cited by 13
New Definition of Aging? Measuring Regenerative Capacity in Patients
Losordo, D. W., & Henry, T. D. (2016) · Circulation Research · doi:10.1161/circresaha.116.309622 · Cited by 7
Cited by
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundEnergy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031264 · Cited by 254
Metadata
- Authors
- Lv, Z., & Guo, Y.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-16
- Volume
- 11
- Pages
- 191-191
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3016349896
- Cited by
- 535
- References
- 115
- FWCI
- 19.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.